New Nordic fund prone for second investment – pours millions into antiviral spinout
In cooperation with the Danish Growth Fund, the recently launched life science fund Eir Ventures has invested a few million dollars into biotech firm Synklino, which is developing an antiviral medication with an annual revenue outlook of USD 1 billion.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL FRANK CHRISTENSEN
The recent capital injection of DKK 409 million (USD 64.28 million) into biotech firm Galecto marked the first investment of the newly established Nordic life science fund Eir Ventures.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
FDA plans new sales channel for hearing aids in autumn
For abonnenter
